Literature DB >> 29338089

Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy.

Mona Kamal1,2, Abdallah S R Mohamed1,3, Clifton David Fuller1, Erich M Sturgis4, Faye M Johnson5,6, William H Morrison1, G Brandon Gunn1, Katherine A Hutcheson4, Jack Phan1, Stefania Volpe1,7, Sweet Ping Ng1, Renata Ferrarotto5, Steven J Frank1, Heath D Skinner1, David I Rosenthal1, Adam S Garden1.   

Abstract

BACKGROUND: There are few published studies to guide the treatment of carcinoma metastatic to the neck from an unknown primary (CUP). In this regard, the objective of the current study was to share the authors' current experience treating patients with CUP using intensity-modulated radiation therapy (IMRT), which principally targeted both sides of the neck, the nasopharynx, and the oropharynx.
METHODS: This was a retrospective study in which an institutional database search was conducted to identify patients with CUP who received IMRT. Data analysis included frequency tabulation, survival analysis, and multivariable analysis.
RESULTS: Two-hundred sixty patients met inclusion criteria. The most common lymph node category was N2b (54%). IMRT volumes included the entire pharyngolaryngeal mucosa in 78 patients, the nasopharynx and oropharynx in 167 patients, and treatment limited to the involved neck in 11 patients. Eighty-four patients underwent neck dissections. The 5-year overall survival, regional control, and distant metastases-free survival rates were 84%, 91%, and 94%, respectively. Over 40% of patients had gastrostomy tubes during therapy, and 7% patients were diagnosed with chronic radiation-associated dysphagia. Higher lymph node burden was associated with worse disease-related outcomes, and in subgroup analysis, patients with human papillomavirus-associated disease had better outcomes. No therapeutic modality was statistically associated with either disease-related outcomes or toxicity.
CONCLUSIONS: Comprehensive IMRT with treatment to both sides of the neck and to the oropharyngeal and nasopharyngeal mucosa results in high rates of disease control and survival. The investigators were unable to demonstrate that treatment intensification with chemotherapy or surgery added benefit or excessive toxicity. Cancer 2018;124:1415-27.
© 2018 American Cancer Society. © 2018 American Cancer Society.

Entities:  

Keywords:  head and neck neoplasms; intensity-modulated radiation therapy; squamous cell carcinoma; unknown primary neoplasms

Mesh:

Year:  2018        PMID: 29338089     DOI: 10.1002/cncr.31235

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage.

Authors:  Mona Kamal; Abdallah S R Mohamed; Clifton David Fuller; Erich M Sturgis; Faye M Johnson; William H Morrison; G Brandon Gunn; Katherine A Hutcheson; Jack Phan; Stefania Volpe; Sweet Ping Ng; Jae Phan; Carlos Cardenas; Renata Ferrarotto; Steven J Frank; David I Rosenthal; Adam S Garden
Journal:  Adv Radiat Oncol       Date:  2020-05-15

2.  Long-term results of elective mucosal irradiation for head and neck cancer of unknown primary in Chinese population: The EMICUP study.

Authors:  Shengjin Dou; Rongrong Li; Lin Zhang; Zhuoying Wang; Li Xie; Chenping Zhang; Guopei Zhu
Journal:  Cancer Med       Date:  2020-01-17       Impact factor: 4.452

3.  Failure patterns of cervical lymph nodes in metastases of unknown origin according to target volume.

Authors:  Dong-Yun Kim; Dae Seog Heo; Bhumsuk Keam; Chan Young Ock; Soon Hyun Ahn; Ji-Hoon Kim; Kyeong Cheon Jung; Jin Ho Kim; Hong-Gyun Wu
Journal:  Radiat Oncol J       Date:  2020-03-30

4.  Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life.

Authors:  Alexander D Sherry; Dario Pasalic; G Brandon Gunn; C David Fuller; Jack Phan; David I Rosenthal; William H Morrison; Erich M Sturgis; Neil D Gross; Maura L Gillison; Renata Ferrarotto; Adel K El-Naggar; Adam S Garden; Steven J Frank
Journal:  Int J Part Ther       Date:  2021-06-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.